Session #5: Toward Personalized microRNA Therapeutics

Presenter Information

Frank Slack, Harvard Medical School

Loading...

Media is loading
 

Event Website

https://cm.jefferson.edu/big-data-september-2020/

Start Date

9-9-2020 12:00 PM

End Date

9-9-2020 12:30 PM

Description

We study the roles and uses of microRNAs and their targets in development, disease, and aging. We were part of the team that discovered the first human microRNA, let-7 and subsequently showed that it is a tumor suppressor that controls key cancer genes, such as RAS, MYC, and LIN28. We are developing let-7 and a second microRNA, miR-34, as novel cancer therapeutics with miR-34 already in Phase I clinical trials. We also proved that microRNAs act as oncogenes and developed strategies to target these oncomiRs for cancer therapy. One of these oncomiRs, miR-155 is currently in Phase I clinical trials for lymphoma. Our research also extends to discovery of additional novel small RNAs in development, cancer, aging, and diabetes as well as identifying novel single nucleotide polymorphisms (SNPs) in the non-coding portions of the genome with an eye to identifying the next generation of targets in cancer.

Comments

Presentation: 16:10

This document is currently not available here.

Share

COinS
 
Sep 9th, 12:00 PM Sep 9th, 12:30 PM

Session #5: Toward Personalized microRNA Therapeutics

We study the roles and uses of microRNAs and their targets in development, disease, and aging. We were part of the team that discovered the first human microRNA, let-7 and subsequently showed that it is a tumor suppressor that controls key cancer genes, such as RAS, MYC, and LIN28. We are developing let-7 and a second microRNA, miR-34, as novel cancer therapeutics with miR-34 already in Phase I clinical trials. We also proved that microRNAs act as oncogenes and developed strategies to target these oncomiRs for cancer therapy. One of these oncomiRs, miR-155 is currently in Phase I clinical trials for lymphoma. Our research also extends to discovery of additional novel small RNAs in development, cancer, aging, and diabetes as well as identifying novel single nucleotide polymorphisms (SNPs) in the non-coding portions of the genome with an eye to identifying the next generation of targets in cancer.

https://jdc.jefferson.edu/biginbigdata/2020/sep9/8